Evidence map›Paper›PMID 38681872›Full record

ArticleNano today2024

Reprogramming the pancreatic cancer stroma and immune landscape by a silicasome nanocarrier delivering nintedanib, a protein tyrosine kinase inhibitor.

Lijia Luo, Xiang Wang, Yu-Pei Liao, Xiao Xu, Chong Hyun Chang, Andre E Nel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nano today, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Targeting Lysosomes for Enhanced Anti-Cancer Therapeutics and Immune Response.International journal of biological sciences · 2026
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lijia LuoDivision of Nanomedicine, Department of Medicine, University of California, Los Angeles, CA 90095, USA.
Xiang WangDivision of Nanomedicine, Department of Medicine, University of California, Los Angeles, CA 90095, USA.
Yu-Pei LiaoDivision of Nanomedicine, Department of Medicine, University of California, Los Angeles, CA 90095, USA.
Xiao XuDivision of Nanomedicine, Department of Medicine, University of California, Los Angeles, CA 90095, USA.
Chong Hyun ChangCalifornia NanoSystems Institute, University of California, Los Angeles, CA 90095, USA.
Andre E NelDivision of Nanomedicine, Department of Medicine, University of California, Los Angeles, CA 90095, USA.

Funding

Use of a Nano-Enabled Platform for Pancreatic Cancer ImmunotherapyR01CA247666 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NEL, ANDRE ELIAS, ZINK, JEFFREY I · 2020 to 2024
$2.6M
NCI NIH HHS R01 CA247666
6 · The paper itself

Abstract

The prevailing desmoplastic stroma and immunosuppressive microenvironment within pancreatic ductal adenocarcinoma (PDAC) pose substantial challenges to therapeutic intervention. Despite the potential of protein tyrosine kinase (PTK) inhibitors in mitigating the desmoplastic stromal response and enhancing the immune milieu, their efficacy is curtailed by suboptimal pharmacokinetics (PK) and insufficient tumor penetration. To surmount these hurdles, we have pioneered a novel strategy, employing lipid bilayer-coated mesoporous silica nanoparticles (termed "silicasomes") as a carrier for the delivery of Nintedanib. Nintedanib, a triple PTK inhibitor that targets vascular endothelial growth factor, platelet-derived growth factor and fibroblast growth factor receptors, was encapsulated in the pores of silicasomes via a remote loading mechanism for weak bases. This innovative approach not only enhanced pharmacokinetics and intratumor drug concentrations but also orchestrated a transformative shift in the desmoplastic and immune landscape in a robust orthotopic KRAS-mediated pancreatic carcinoma (KPC) model. Our results demonstrate attenuation of vascular density and collagen content through encapsulated Nintedanib treatment, concomitant with significant augmentation of the CD8

Indexed as

Anti-angiogenesisDrug deliveryImmunotherapyPancreatic cancerPTK inhibitorTumor stroma

Identifiers

PMID38681872
PMCPMC11044875

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.